Antibodies, when optimized by our immune system, effectively target specific pathogens or diseases, making them an invaluable asset for developing medications with minimal side effects.
The first medical antibody approved was muromonab-CD3 in 1986, aimed at preventing organ rejection, demonstrating the potential of antibodies in clinical therapies.
Current research focuses on leveraging antibodies to address aging, with the potential to mitigate diseases like cancer and dementia, enhancing longevity and quality of life.
Through careful targeting of processes involved in disease, antibodies may not only treat illnesses but also delay the adverse effects linked to the aging process.
Collection
[
|
...
]